http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022251375-A3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_06b1684e84fd9a9c6e2889d8aadbf0f6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fd4017cba91704411f50b544d438fba1 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6806 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-154 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2022-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da113b299579ee8771db02f2d163fe3d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50b4273af0befe8d883768122456956a |
| publicationDate | 2023-01-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022251375-A3 |
| titleOfInvention | Epigenetic moderators of naltrexone efficacy efficacy in reducing heavy drinking in individuals diagnosed with alcohol use disorder |
| abstract | Disclosed are method for predicting naltrexone response in subjects with AUD. In some embodiments, the methods include performing or having performed one or more methylation assays on a genomic DNA sample isolated from the subject to determine the methylation status of one or more regions of the isolated genomic DNA, wherein the one or more regions are subsequences of a gene selected from a mu opioid receptor (OPRM1) gene, a catechol-O-methyltransferase (COMT) gene, and a dopamine transporter (SLC6A3) gene, wherein the methylation status of the one or more regions of the isolated genomic DNA determined is predictive of naltrexone response in the subject. Also provided are method for treating patients diagnosed with AUD with the medication naltrexone based on a methylation status of a combination of specific methylation sites located associated with an OPRM1 gene, a COMT gene, and/or an SLC6A3 gene in obtained from each AUD patient. |
| priorityDate | 2021-05-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 52.